Risk factors associated with hemorrhagic cystitis on multivariable analysis
Risk factors . | Odds ratio (95% CI) . | P . |
|---|---|---|
| HC* | ||
| BK before or during HC | 30 (5.5-173) | < .001 |
| Busulfan/cyclophosphamide | 8.6 (1.7-44) | .003 |
| BK viremia before HC | 11 (3.3-34) | < .001 |
| Busulfan/cyclophosphamide | 4.3 (1.3-14) | .012 |
| Postengraftment BK-HC† | ||
| BK before or during HC | 20 (3.6-inf) | <.001 |
| Busulfan/cyclophosphamide | 9.2 (1.1-inf) | .037 |
| BK viremia before HC | 17 (2.8-683) | <.001 |
| Busulfan/cyclophosphamide | 9.3 (0.61-678) | .15 |
Risk factors . | Odds ratio (95% CI) . | P . |
|---|---|---|
| HC* | ||
| BK before or during HC | 30 (5.5-173) | < .001 |
| Busulfan/cyclophosphamide | 8.6 (1.7-44) | .003 |
| BK viremia before HC | 11 (3.3-34) | < .001 |
| Busulfan/cyclophosphamide | 4.3 (1.3-14) | .012 |
| Postengraftment BK-HC† | ||
| BK before or during HC | 20 (3.6-inf) | <.001 |
| Busulfan/cyclophosphamide | 9.2 (1.1-inf) | .037 |
| BK viremia before HC | 17 (2.8-683) | <.001 |
| Busulfan/cyclophosphamide | 9.3 (0.61-678) | .15 |
Platelet engraftment was defined as a platelet count greater than 20 × 109/L without transfusion support for 7 consecutive days.
The following factors were entered as covariates: sex, CMV serostatus, CMV infection before HC (antigenemia or plasma PCR positive), source of stem cells (peripheral blood stem cells versus bone marrow), conditioning regimen (busulfan/cyclophosphamide versus others), presence of GVHD (grade = 2) prior to HC, and HLA matching (HLA match versus other). Total body irradiation (TBI) was not entered in the multivariate model due to its high correlation with busulfan and cyclophosphamide regimen (ie, 94% of patients who received busulfan and cyclophosphamide did not receive TBI). Among patients undergoing other regimens, 92% received TBI.
All cases of HC: 30 patients and 81 controls. Variables associated with HC in univariate analysis: BK before or during HC versus no viremia (OR, 20; 95% CI, 4.6-85; P < .001); BK before HC versus no viremia (OR, 10; 95% CI, 3.4- 30; P < .001); use of busulfan and cyclophosphamide regimen versus other regimens (OR, 3.7; 95% CI, 1.4-9.9; P = .006); any busulfan versus no busulfan (OR, 5.6; 95% CI, 1.8-17; P < .001)
Patients who presented with HC after platelet engraftment and had documented BK viruria: 14 patients and 37 controls. Variables associated with postengraftment HC in univariate analysis: BK before or during HC versus no viremia (OR, 20; 95% CI, 2.7-802; P < .001); BK before HC versus no viremia (OR, 13; 95% CI, 3.4-30; P < .001); use of busulfan/cyclophosphamide regimen versus other regimens (OR, 5.0; 95% CI, 0.97-25; P = .03); any busulfan versus no busulfan (OR, 10; 95% CI, 1.2-86; P < .006)